MASH Diagnostics: Advances, Limitations, and the Path Ahead (Session 2)
Nov
10
2025
Convention Center: Ballroom A, Level 3
11:00 AM
- 12:30 PM
World Class Speakers
Description
Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.Journey Maps
Presentations
11:00 AM
- 11:15 AM
Aug
06
2026
Convention Center - Ballroom A, Level 3
A Randomized Controlled Trial in Silico for Risk Stratification in Population Screening for Fibrotic MASH
Rashmee Patil, MD
, Abstract Presenter
MASLD
11:15 AM
- 11:30 AM
Aug
06
2026
Convention Center - Ballroom A, Level 3
ONE-YEAR CHANGES IN ALT AND LSM, BUT NOT IN CAP, PREDICT LONG-TERM LIVER OUTCOMES IN PATIENTS WITH MASLD
Jeffrey V. Lazarus, PhD
, Abstract Presenter
MASLD
11:30 AM
- 11:45 AM
Aug
06
2026
Convention Center - Ballroom A, Level 3
Performance of Expert Panel Criteria in Predicting At-Risk and Not-At-Risk MASH: Data from a Large Multi-Center Cohort
Rashmee Patil, MD
, Abstract Presenter
MASLD
11:45 AM
- 12:00 PM
Aug
06
2026
Convention Center - Ballroom A, Level 3
Missed Liver Fibrosis Risk Stratification Opportunities in the All of Us Cohort in the United States
Jeffrey V. Lazarus, PhD
, Abstract Presenter
MASLD
12:00 PM
- 12:15 PM
Aug
06
2026
Convention Center - Ballroom A, Level 3
Factors Associated with Ballooning vs. No Ballooning in Patients with F2/F3 Fibrosis: Data from Multicenter MASH Randomized Clinical Trials
Rashmee Patil, MD
, Abstract Presenter
MASLD
Objectives
- Review recent advancements in noninvasive diagnostic tools and biomarkers for MASH, including their clinical utility and validation status
- Discuss limitations, uncertainties, and practical challenges in implementing MASH diagnostics in clinical and research settings.